MARKET

PGEN

PGEN

Precigen Inc
NASDAQ

Real-time Quotes | Nasdaq Last Sale

3.750
-0.400
-9.64%
After Hours: 3.690 -0.06 -1.60% 18:24 09/23 EDT
OPEN
4.160
PREV CLOSE
4.150
HIGH
4.170
LOW
3.730
VOLUME
1.25M
TURNOVER
--
52 WEEK HIGH
7.28
52 WEEK LOW
1.260
MARKET CAP
646.17M
P/E (TTM)
-3.2903
1D
5D
1M
3M
1Y
5Y
News
Financial
Releases
Corp Actions
Analysis
Profile
Precigen (PGEN) Presents at H.C. Wainwright Annual Global Investment Conference - Slideshow
The following slide deck was published by Precigen, Inc. in conjunction with this event.
Seekingalpha · 5d ago
Precigen to Present at H.C. Wainwright 22nd Annual Global Investment Conference
Precigen, Inc. (Nasdaq: PGEN), a biopharmaceutical company specializing in the development of innovative gene and cell therapies to improve the lives of patients, today announced Helen Sabzevari, PhD, President and CEO of Precigen, will present at the virtual H.C. Wainwright 22nd Annual Global Investment
PR Newswire · 09/08 11:30
Could The Precigen, Inc. (NASDAQ:PGEN) Ownership Structure Tell Us Something Useful?
If you want to know who really controls Precigen, Inc. (NASDAQ:PGEN), then you'll have to look at the makeup of its...
Simply Wall St. · 08/21 16:14
Precigen shares are trading higher after the company announced the first patient has been dosed its Phase I/II study of PRGN-2009 to treat HPV-associated cancers.
Benzinga · 08/17 15:50
Precigen Announces First Patient Dosed in Phase I/II Study of First-in-Class PRGN-2009 AdenoVerse Immunotherapy to Treat HPV-associated Cancers
Precigen, Inc. (Nasdaq: PGEN), a biopharmaceutical company specializing in the development of innovative gene and cellular therapies to improve the lives of patients, today announced that the first patient has been dosed with Precigen's PRGN-2009, a first-in-class, off-the-shelf (OTS) investigational
PR Newswire · 08/17 12:30
Precigen initiates early-stage study with PRGN-2009 in HPV associated cancer
Precigen (PGEN) +1.8% in premarket, has dosed first patient with its's PRGN-2009 in Phase 1/2 trial. The product candidate is an off-the-shelf immunotherapy that utilizes AdenoVerse platform designed to activate the immune system to recognize
Seekingalpha · 08/17 11:47
Precigen initiates early-stage study of PRGN-2009 in HPV-associated cancer
Precigen (PGEN) +1.8% in premarket, has dosed the first patient with PRGN-2009 in a Phase 1/2 trial. The product candidate is an off-the-shelf immunotherapy that utilizes AdenoVerse platform designed to activate the immune system to recognize and
Seekingalpha · 08/17 11:47
Precigen Announces First Patient Dosed in Phase I/II Study of First-in-Class PRGN-2009 AdenoVerse Immunotherapy to Treat HPV-associated Cancers
Benzinga · 08/17 11:32
More
Forecast
EPSBVPSCFPS
Actual (USD)
Estimate (USD)
Income StatementMore
Net IncomeTotal RevenueOperating Income
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
OperatingInvestingFinancing
Operating (USD)
YoY (%)
Learn about the latest financial forecast of PGEN. Analyze the recent business situations of Precigen Inc through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 3 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average PGEN stock price target is 8.50 with a high estimate of 13.00 and a low estimate of 6.00.
EPS
Institutional Holdings
Institutions: 256
Institutional Holdings: 123.36M
% Owned: 71.59%
Shares Outstanding: 172.31M
TypeInstitutionsShares
Increased
38
2.73M
New
45
-5.46M
Decreased
44
5.11M
Sold Out
0
0
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Biotechnology & Medical Research
-2.78%
Pharmaceuticals & Medical Research
-1.14%
Key Executives
Chairman/Executive Director
Randal Kirk
President/Chief Executive Officer
Helen Sabzevari
Chief Financial Officer/Primary Contact
Rick Sterling
Senior Vice President
Jeffrey Perez
Executive Officer
Donald Lehr
Lead Director/Independent Director
Robert Shapiro
Independent Director
Cesar Alvarez
Independent Director
Steven Frank
Independent Director
Vinita Gupta
Independent Director
Fred Hassan
Independent Director
Jeffrey Kindler
Independent Director
Dean Mitchell
Independent Director
James Turley
  • Dividends
  • Splits
  • Insider Activity
Declaration Date
Dividend Per Share
Ex-Div Date
06/08/2015
Dividend USD 0.162
06/09/2015
Access Level 2 Advance
Nasdaq TotalView
for Free
Get Now
About PGEN
Precigen, Inc., formerly Intrexon Corporation, forms collaborations to create biologically-based products and processes using synthetic biology. The Company's domestic operations are in California, Florida, Maryland, and Virginia, and its primary international operations are in Belgium and Hungary. The Company designs, builds and regulates gene programs, which are deoxyribonucleic acid (DNA) sequences that consist of genetic components. The Company's synthetic biology capabilities include the ability to control the amount, location and modification of biological molecules to control the function and output of living cells and optimize for desired results at an industrial scale. The Company's technologies include UltraVector gene design and fabrication platform, and its associated library of modular DNA components; Cell Systems Informatics; RheoSwitch inducible gene switch; AttSite Recombinases; Protein Engineering; Laser-Enabled Analysis and Processing (LEAP), and ActoBiotics platform.
More
Hot Stocks
Symbol
Price
%Change

Webull offers kinds of Precigen Inc stock information, including NASDAQ:PGEN real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, PGEN stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading PGEN stock methods without spending real money on the virtual paper trading platform.